



10/501496  
PCT/EP 03/01227  
Rec'd PCT/PTO 14 JUL 2004



#2

INVESTOR IN PEOPLE

REC'D 28 FEB 2003

The Patent Office

WIPO Copyright House

Cardiff Road

Newport

South Wales

NP10 8QQ


**PRIORITY DOCUMENT**  
SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH  
RULE 17.1(a) OR (b)

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



Signed

*P. Mahoney*

Dated

4 December 2002

**BEST AVAILABLE COPY**

**Patents Form 1/77**

**Patents Act 1977**  
(Rule 16)

**The  
Patent  
Office**

**1 / 77**

**Request for grant of a patent**

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

**The Patent Office**

Cardiff Road  
Newport  
Gwent NP10 8QQ

1. Your reference **4-32352P1/HO 55**

2. Patent application

**0203061.7**

**8 FEB 2002**

Address and postcode of the  
of each applicant  
(underline all surnames)

**NOVARTIS AG  
LICHTSTRASSE 35  
4056 BASEL  
SWITZERLAND**

Patent ADP number (if you know it)

If the applicant is a corporate body,  
give the country/state of its  
incorporation

**SWITZERLAND**

**712 548 7001**

4. Title of invention

**Organic Compounds**

5. Name of your agent (If you have one)

"Address for service" in the United  
Kingdom to which all correspondence  
should be sent  
(including the postcode)

**B.A. YORKE & CO.  
CHARTERED PATENT AGENTS  
COOMB HOUSE, 7 ST. JOHN'S ROAD  
ISLEWORTH  
MIDDLESEX TW7 6NH**

Patents ADP number (if you know it)

**1800001**

6. If you are declaring priority from one  
ore more earlier patent applications,  
give  
the country and the date of filing of  
the or of each of these earlier  
applications and (if you know it) the or  
each application number

Country

Priority application  
number  
(if you know it)

Date of filing  
(day/month/year  
)

7. If this application is divided or  
otherwise derived from an earlier UK  
application, give the number and the  
filing date of the earlier application

Number of earlier  
application

Date of filing  
(day/month/year)

8. Is a statement of inventorship and of  
right to grant of a patent required in  
support of this request? (Answer 'Yes' if:

**Yes**

- a) any applicant named in part 3 is not an inventor, or
- b) there is an inventor who is not named as an applicant, or
- c) any named applicant is a corporate body.

(see note (d))

## Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form

Description 10  
Claim(s) 3  
Abstract  
Drawing(s)

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (*Patents Form 7/77*)

Request for preliminary examination and search (*Patents Form 9/77*)

Request for substantive examination (*Patents Form 10/77*)

Any other documents  
(please specify)

ONE

11.

I/We request the grant of a patent on the basis of this application

Signature

Date

B.A. Yorke & Co.

B.A. Yorke & Co.

08 February 2002

12. Name and daytime telephone number of person to contact in the United Kingdom

Mrs. E. Cheetham  
020 8560 5847

### Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.


### Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay please contact the Patent Office.

### Organic Compounds

This invention relates to organic compounds and, in particular to their use as pharmaceuticals.

The invention provides, in one aspect, use of a compound of formula I



in free form or in the form of a pharmaceutically acceptable salt for the preparation of a medicament for the treatment of a functional motility disorder of the viscera, wherein

R<sup>1</sup> is phenyl that is unsubstituted or is substituted by 1, 2 or 3 substituents selected from the group halogen, C<sub>1</sub>-C<sub>7</sub>-alkyl, trifluoromethyl, hydroxy and C<sub>1</sub>-C<sub>7</sub>-alkoxy,

R<sup>2</sup> is hydrogen or C<sub>1</sub>-C<sub>7</sub>-alkyl,

R<sup>3</sup> is hydrogen, C<sub>1</sub>-C<sub>7</sub>-alkyl or phenyl that is unsubstituted or is substituted by 1, 2 or 3 substituents selected from the group halogen, C<sub>1</sub>-C<sub>7</sub>-alkyl, trifluoromethyl, hydroxy and C<sub>1</sub>-C<sub>7</sub>-alkoxy,

R<sup>4</sup> is phenyl that is unsubstituted or is substituted by 1, 2 or 3 substituents selected from the group halogen, C<sub>1</sub>-C<sub>7</sub>-alkyl, trifluoromethyl, hydroxy and C<sub>1</sub>-C<sub>7</sub>-alkoxy; or is naphthyl, 1H-indol-3-yl or 1-C<sub>1</sub>-C<sub>7</sub>-alkyl-indol-3-yl,

R<sup>5</sup> and R<sup>6</sup> are each independently of the other hydrogen or C<sub>1</sub>-C<sub>7</sub>-alkyl, at least one of R<sup>5</sup> and R<sup>6</sup> being hydrogen, and

R<sup>7</sup> is C<sub>3</sub>-C<sub>8</sub>-cycloalkyl, D-azacycloheptan-2-on-3-yl or L-azacycloheptan-2-on-3-yl.

The invention provides, in another aspect, a method of treating a functional motility disorder of the viscera, in a subject, particularly a human subject, in need of such treatment, which comprises administering to said subject an effective amount of a compound of formula I as hereinbefore defined.

Treatment of a functional motility disorder of the viscera in accordance with the invention may be symptomatic or prophylactic (preventative).

Functional motility disorders of the viscera to be treated in accordance with the invention include those associated with visceral hypersensitivity and/or altered motor responses (including electrolyte/water secretion), for example functional bowel disorders and functional gastrointestinal disorders, such as irritable bowel syndrome (IBS), constipation, diarrhoea, functional dyspepsia, gastro-oesophageal reflux disease, functional abdominal bloating, and functional abdominal pain, other conditions associated with visceral hypersensitivity such as post-operative visceral pain, visceral smooth muscle spasms, and irritable bladder and other functional bowel disorders (not necessarily associated with visceral hypersensitivity or abnormal motor responses). The invention is of particular importance for the treatment of irritable bowel syndrome (IBS), especially diarrhoea- predominant IBS, and functional dyspepsia (FD).

The general terms used hereinabove and hereinbelow preferably have the following meanings:

C<sub>1</sub>-C<sub>7</sub>-alkyl is, for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, neopentyl, n-hexyl or n-heptyl, preferably C<sub>1</sub>-C<sub>4</sub>alkyl, especially methyl or ethyl, and more especially methyl.

Halogen is, for example, fluorine, chlorine, bromine or iodine.

Halophenyl is, for example, (fluoro-, chloro-, bromo- or iodo-)phenyl, preferably fluorophenyl or chlorophenyl, especially 4-fluorophenyl or 4-chlorophenyl, and more especially 4-chlorophenyl.


Dihalophenyl is, for example, dichlorophenyl, difluorophenyl or chlorofluorophenyl, preferably dichlorophenyl or difluorophenyl, especially 3,4-dichlorophenyl or 3,4-difluorophenyl, and more especially 3,4-dichlorophenyl.

Trihalophenyl is, for example, trifluorophenyl or trichlorophenyl.


1-C<sub>1</sub>-C<sub>7</sub>-alkyl-indol-3-yl is, for example, 1-methyl-indol-3-yl.

C<sub>3</sub>-C<sub>8</sub>-Cycloalkyl - and analogously C<sub>5</sub>-C<sub>7</sub>-cycloalkyl - is in each case a cycloalkyl radical having the number of ring carbon atoms indicated. C<sub>3</sub>-C<sub>8</sub>-Cycloalkyl is therefore, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl, preferably cyclohexyl.

D-Azacycloheptan-2-on-3-yl corresponds to the following group




which is derived from D(+)-epsilon-caprolactam (amino-)substituted in the 3-position [ $\approx$  D-3-amino-epsilon-caprolactam = (R)-3-amino-hexahydro-2-azepinone]. Analogously, L-azacycloheptan-2-on-3-yl corresponds to the group




which is derived from L(-)-epsilon-caprolactam (amino-)substituted in the 3-position [ $\approx$  L-3-amino-epsilon-caprolactam = (S)-3-amino-hexahydro-2-azepinone].

The compounds of formula I may be of formula IA



where \* denotes the R configuration, or of formula IB



where \* denotes the S configuration, where R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup> and R<sup>7</sup> are as hereinbefore defined.

Compounds of formula IA are usually preferred for use in accordance with the invention.

Compounds of formula I having a basic group may, for example, form acid addition salts with suitable mineral acids, such as hydrohalic acids, sulfuric acid or phosphoric acid, for example hydrochlorides, hydrobromides, sulfates, hydrogen sulfates or phosphates. Where the compounds of formula I contain an acid group, corresponding salts with bases are also possible, for example corresponding alkali metal or alkaline earth metal salts, for example sodium, potassium or magnesium salts, or salts with ammonia or organic amines, for example ammonium salts.

The invention relates preferably to the use of compounds of formula I wherein

R<sup>1</sup> is phenyl, 3,5-bistrifluoromethyl-phenyl or 3,4,5-trimethoxyphenyl,

R<sup>2</sup> is hydrogen or C<sub>1</sub>-C<sub>7</sub>-alkyl,

R<sup>3</sup> is hydrogen or phenyl,

R<sup>4</sup> is phenyl, halo-phenyl, dihalo-phenyl, trihalo-phenyl, 2-naphthyl, 1H-indol-3-yl or 1-C<sub>1</sub>-C<sub>7</sub>-alkyl-indol-3-yl,

R<sup>5</sup> and R<sup>6</sup> are each independently of the other hydrogen or C<sub>1</sub>-C<sub>7</sub>-alkyl, at least one of R<sup>5</sup> and R<sup>6</sup> being hydrogen, and

R<sup>7</sup> is C<sub>5</sub>-C<sub>7</sub>cycloalkyl, D-azacycloheptan-2-on-3-yl or L-azacycloheptan-2-on-3-yl.

The invention relates especially to the use of compounds of formula I wherein

R<sup>1</sup> is 3,5-bistrifluoromethyl-phenyl,

R<sup>2</sup> is hydrogen, methyl or ethyl,

R<sup>3</sup> is hydrogen or phenyl,

R<sup>4</sup> is phenyl, 4-chlorophenyl, 4-fluorophenyl, 3,4-dichloro-phenyl, 3,4-difluoro-phenyl, 3-fluoro-4-chloro-phenyl, 3,4,5-trifluoro-phenyl, 2-naphthyl, 1H-indol-3-yl or 1-methyl-indol-3-yl,

R<sup>5</sup> and R<sup>6</sup> are each independently of the other hydrogen or methyl, at least one of R<sup>5</sup> and R<sup>6</sup> being hydrogen, and

R<sup>7</sup> is cyclohexyl, D-azacycloheptan-2-on-3-yl or L-azacycloheptan-2-on-3-yl.

The invention relates more especially to the use of compounds of formula I wherein

R<sup>1</sup> is 3,5-bistrifluoromethyl-phenyl,

R<sup>2</sup> is hydrogen or methyl,

R<sup>3</sup> is hydrogen or phenyl,

R<sup>4</sup> is phenyl, 4-chlorophenyl, 3,4-dichloro-phenyl, 2-naphthyl, 1H-indol-3-yl or 1-methyl-indol-3-yl,

R<sup>5</sup> and R<sup>6</sup> are hydrogen, and

R<sup>7</sup> is cyclohexyl, D-azacycloheptan-2-on-3-yl or L-azacycloheptan-2-on-3-yl.

Special mention should be made of each of the following sub-groups of a group of compounds of formula I:

(1) compounds of formula I wherein R<sup>7</sup> is D-azacycloheptan-2-on-3-yl; (2) compounds of formula I wherein R<sup>5</sup> and R<sup>6</sup> are hydrogen; (3) compounds of formula I wherein R<sup>1</sup> is phenyl, 3,5-bistrifluoromethyl-phenyl or 3,4,5-trimethoxyphenyl; (4) compounds of formula I in free form, that is to say not in the form of a salt.

Specific examples of compounds of formula I include


(4R)-[N'-methyl-N'-(3,5-bistrifluoromethyl-benzoyl)-amino]-5-(1-methyl-indol-3-yl)-pent-2-enoic acid N-[(R)-epsilon-caprolactam-3-yl]-amide,  
(4R)-[N'-methyl-N'-(3,5-bistrifluoromethyl-benzoyl)-amino]-5-(1-methyl-indol-3-yl)-pent-2-enoic acid N-[(S)-epsilon-caprolactam-3-yl]-amide,  
(4R)-[N'-methyl-N'-(3,5-bistrifluoromethyl-benzoyl)-amino]-5-(1-methyl-indol-3-yl)-pent-2-enoic acid N-cyclohexyl-amide,  
(4R)-[N'-methyl-N'-(3,5-bistrifluoromethyl-benzoyl)-amino]-5-(1-methyl-indol-3-yl)-2-methyl-pent-2-enoic acid N-cyclohexyl-amide,  
(4R)-[N'-methyl-N'-(3,5-bistrifluoromethyl-benzoyl)-amino]-5-(1-methyl-indol-3-yl)-2-methyl-pent-2-enoic acid N-[(R)-epsilon-caprolactam-3-yl]-amide,  
(4R)-[N'-methyl-N'-(3,5-bistrifluoromethyl-benzoyl)-amino]-5-(1-methyl-indol-3-yl)-2-methyl-pent-2-enoic acid N-[(S)-epsilon-caprolactam-3-yl]-amide,  
(4R)-(N'-methyl-N'-benzoyl-amino)-5-(1-methyl-indol-3-yl)-2-methyl-pent-2-enoic acid N-[(R)-epsilon-caprolactam-3-yl]-amide,  
(4R)-[N'-methyl-N'-(3,5-bistrifluoromethyl-benzoyl)-amino]-5-(naphth-2-yl)-pent-2-enoic acid N-[(R)-epsilon-caprolactam-3-yl]-amide,  
(4R)-(N'-methyl-N'-benzoyl)-amino-5-(naphth-2-yl)-pent-2-enoic acid N-[(R)-epsilon-caprolactam-3-yl]-amide,



(4R)-[N'-methyl-N'-(3,5-bis(trifluoromethyl)benzoyl)-amino]-5-(naphth-2-yl)-2-methyl-pent-2-enoic acid N-[(R)-epsilon-caprolactam-3-yl]-amide,  
(4R)-[N'-methyl-N'-(3,4,5-trimethoxybenzoyl)-amino]-5-(naphth-2-yl)-2-methyl-pent-2-enoic acid N-[(R)-epsilon-caprolactam-3-yl]-amide,  
(4R)-[N'-methyl-N'-(3,5-bis(trifluoromethyl)benzoyl)-amino]-5-(naphth-2-yl)-2-methyl-pent-2-enoic acid N-[(S)-epsilon-caprolactam-3-yl]-amide,  
(4R)-[N'-methyl-N'-(3,5-bis(trifluoromethyl)benzoyl)-amino]-5-(naphth-2-yl)-2-methyl-pent-2-enoic acid N-cyclohexyl-amide,  
(4R)-[N'-methyl-N'-(3,5-bis(trifluoromethyl)benzoyl)-amino]-5-(1-methyl-indol-3-yl)-pent-2-enoic acid N-[(S)-epsilon-caprolactam-3-yl]-amide,  
(4R)-[N'-methyl-N'-(3,5-bis(trifluoromethyl)benzoyl)-amino]-4-(4-chlorobenzyl)-but-2-enoic acid N-[(R)-epsilon-caprolactam-3-yl]-amide,  
(4R)-[N'-methyl-N'-(3,5-bis(trifluoromethyl)benzoyl)-amino]-4-(4-chlorobenzyl)-but-2-enoic acid N-[(S)-epsilon-caprolactam-3-yl]-amide,  
(4R)-[N'-methyl-N'-(3,5-bis(trifluoromethyl)benzoyl)-amino]-4-(4-chlorobenzyl)-but-2-enoic acid N-cyclohexyl-amide,  
(4R)-[N'-methyl-N'-(3,5-bis(trifluoromethyl)benzoyl)-amino]-4-(3,4-dichlorobenzyl)-but-2-enoic acid N-cyclohexyl-amide,  
(4R)-[N'-methyl-N'-(3,5-bis(trifluoromethyl)benzoyl)-amino]-4-(3,4-difluorobenzyl)-but-2-enoic acid N-cyclohexyl-amide,  
(4R)-[N'-methyl-N'-(3,5-bis(trifluoromethyl)benzoyl)-amino]-5-(4-chlorophenyl)-2-methyl-pent-2-enoic acid N-cyclohexylamide,  
(4R)-[N'-methyl-N'-(3,5-bis(trifluoromethyl)benzoyl)-amino]-5-(4-chlorophenyl)-2-methyl-pent-2-enoic acid N-[(R)-epsilon-caprolactam-3-yl]-amide,  
(4R)-[N'-methyl-N'-(3,5-bis(trifluoromethyl)benzoyl)-amino]-4-(4-chlorobenzyl)-2-methyl-but-2-enoic acid [(S)-epsilon-caprolactam-3-yl]-amide,  
(4R)-[N'-ethyl-N'-(3,5-bis(trifluoromethyl)benzoyl)-amino]-5-(4-chlorophenyl)-pent-2-enoic acid N-[(S)-epsilon-caprolactam-3-yl]-amide,  
(4R)-[N'-methyl-N'-(3,5-bis(trifluoromethyl)benzoyl)-amino]-5-(4-chlorophenyl)-3-methyl-pent-2-enoic acid N-cyclohexyl-amide,  
(4R)-[N'-methyl-N'-(3,5-bis(trifluoromethyl)benzoyl)-amino]-4-(4-chlorobenzyl)-3-methyl-but-2-enoic acid [(R)-epsilon-caprolactam-3-yl]-amide,  
(4R)-[N'-methyl-N'-(3,5-bis(trifluoromethyl)benzoyl)-amino]-4-(4-chlorobenzyl)-but-2-enoic acid N-[(R)-epsilon-caprolactam-3-yl]-amide,

(4R)-4-[N'-methyl-N'-(3,5-bistrifluoromethyl-benzoyl)-amino]-4-(3,4-dichlorobenzyl)-but-2-enoic acid N-[(R)-epsilon-caprolactam-3-yl]-amide,  
 (4R)- and (4S)-4-[N'-methyl-N'-(3,5-bistrifluoromethyl-benzoyl)-amino]-4-(3-fluoro-4-chlorobenzyl)-but-2-enoic acid N-[(R)-epsilon-caprolactam-3-yl]-amide,  
 (4R)- and (4S)-4-[N'-methyl-N'-(3,5-bistrifluoromethyl-benzoyl)-amino]-4-(3,4-difluorobenzyl)-but-2-enoic acid N-[(R)-epsilon-caprolactam-3-yl]-amide,  
 (4R)- and (4S)-4-[N'-methyl-N'-(3,5-bistrifluoromethyl-benzoyl)-amino]-4-(3,4-dibromobenzyl)-but-2-enoic acid N-[(R)-epsilon-caprolactam-3-yl]-amide,  
 (4R)- and (4S)-4-[N'-methyl-N'-(3,5-bistrifluoromethyl-benzoyl)-amino]-4-(3,4,5-trifluorobenzyl)-but-2-enoic acid N-[(R)-epsilon-caprolactam-3-yl]-amide,  
 (4R)- and (4S)-4-[N'-methyl-N'-(3,5-bistrifluoromethyl-benzoyl)-amino]-4-(4-fluorobenzyl)-but-2-enoic acid N-[(R)-epsilon-caprolactam-3-yl]-amide,  
 (4R)- and (4S)-[N'-(3,5-bistrifluoromethyl-benzoyl)-N'-methyl-amino]-5,5-diphenyl-pent-2-enoic acid N-[(S)-epsilon-caprolactam-3-yl]-amide,  
 (4S)-4-[N'-methyl-N'-(3,5-bistrifluoromethylbenzoyl)amino]-4-(3,4-dichlorobenzyl)-but-2-enoic acid N-[(R)-epsilon-caprolactam-3-yl]-amide,  
 (4R)-4-[N'-methyl-N'-(3,5-bistrifluoromethylbenzoyl)amino]-4-(3,4-dichlorobenzyl)-but-2-enoic acid N-[(S)-epsilon-caprolactam-3-yl]-amide, and  
 (4S)-4-[N'-methyl-N'-(3,5-bistrifluoromethylbenzoyl)amino]-4-(3,4-dichlorobenzyl)-but-2-enoic acid N-[(S)-epsilon-caprolactam-3-yl]-amide.

The invention relates most importantly to the use of (4R)-4-[N'-methyl-N'-(3,5-bistrifluoromethylbenzoyl)amino]-4-(3,4-dichlorobenzyl)-but-2-enoic acid N-[(R)-epsilon-caprolactam-3-yl]-amide, i.e. a compound of formula



The compounds of formula I, in free or pharmaceutically acceptable salt form, may be prepared as described in WO98/07694 or WO01/85696. As mentioned therein, they may be

in the form of their hydrates and/or may include other solvents, for example solvents which may have been used for the crystallisation of compounds in solid form.

Depending upon the nature of the variables and the corresponding number of centres of asymmetry and also upon the starting materials and procedures chosen, the compounds of formula I may be obtained in the form of mixtures of stereoisomers, for example mixtures of diastereoisomers or mixtures of enantiomers, such as racemates, or possibly also in the form of pure stereoisomers. Mixtures of diastereoisomers obtainable in accordance with the process or by some other method can be separated in customary manner into mixtures of enantiomers, for example racemates, or into individual diastereoisomers, for example on the basis of the physico-chemical differences between the constituents in known manner by fractional crystallisation, distillation and/or chromatography. Advantageously the more active isomer is isolated.

Mixtures of enantiomers, especially racemates, obtainable in accordance with the process or by some other method can be separated into the individual enantiomers by known methods, for example by recrystallisation from an optically active solvent, with the aid of micro-organisms, by chromatography and/or by reaction with an optically active auxiliary compound, for example a base, acid or alcohol, to form mixtures of diastereoisomeric salts or functional derivatives, such as esters, separation thereof and freeing of the desired enantiomer. Advantageously the more active enantiomer is isolated.

In the treatment of disorders in accordance with the invention, compounds of formula I, in free form or in pharmaceutically acceptable salt form, may be administered by any appropriate route, for example orally, e.g. in tablet, capsule or liquid form, parenterally, for example in the form of an injectable solution or suspension, or intranasally, for example in the form of an aerosol or other atomisable formulation using an appropriate intranasal delivery device, e.g. a nasal spray such as those known in the art.

The compound of formula I in free or salt form may be administered in a pharmaceutical composition together with a pharmaceutically acceptable diluent or carrier. Such compositions may be as described in WO98/07694, for example tablets, capsules, liquids, injection solutions, infusion solutions or inhalation suspensions as described in Examples A to E of WO98/07694, or may be prepared using other formulating ingredients and techniques known in the art.

The dosage of the compound of formula I in free or salt form can depend on various factors, such as the activity and duration of action of the active ingredient, the severity of the condition to be treated, the mode of administration, the species, sex, ethnic origin, age and weight of the subject and/or its individual condition. In a normal case the daily dose for administration, for example oral administration, to a warm-blooded animal, particularly a human being, weighing about 75 kg is estimated to be from approximately 1 mg to approximately 1000 mg, especially from approximately 5 mg to approximately 200 mg. That dose may be administered, for example, in a single dose or in several part doses of, for example, from 5 to 100 mg.

The utility of a compound of formula I in the treatment of the disorders hereinbefore described may be demonstrated in an in vivo model of visceral hypersensitivity, for example as described hereinafter in Example 1, in a peristaltic reflex model, for example as described hereinafter in Example 2, or an epithelial secretion model, for example as described hereinafter in Example 3.

The invention is illustrated by the following Examples.

#### Example 1

In conscious guinea pigs, two experimental paradigms are applied to induce visceral hypersensitivity, *i*) restraint stress (immobilization of the animals in a tube) and *ii*) colonic tissue irritation (colonic instillation of acetic acid, 0.6 % in saline, 1.5 ml, 2 cm proximal to the anus). Colorectal distension is performed by inflating a balloon to a net pressure (at the colonic wall) of 20 mmHg (26.7 mbar) for 10 minutes before and following induction of visceral hypersensitivity. During the distension period the visceromotor response, i.e. the number and quality of abdominal contractions (body arching and lifting of pelvic structures) are recorded and quantified in a blinded fashion (Al-Chaer et al., Gastroenterology 2000; 119: 1276-1285). Following the performance of baseline colorectal distension protocols, vehicle or the compound of formula II (3 and 10 mg/kg) are dosed orally one hour prior to the second colorectal distensions, which are done after the induction of visceral hypersensitivity. The effects of vehicle and the compound of formula II are assessed in 6-8 animals. Restraint stress and local tissue irritation by intracolonic instillation of acetic acid significantly exaggerates the visceromotor responses upon colorectal distension by 54.5 % and 29.1 %, respectively, over baseline. The compound of formula II reverses the exaggerated behavioural pain responses upon colorectal balloon distensions in both restraint

stress-induced and tissue irritation-induced colonic hypersensitivity. The reversal in pain responses is statistically significant at both doses tested, 3 and 10 mg/kg p.o. ( $p < 0.05$ ; ANOVA post-hoc Dunnett's test).

#### Example 2


Substance P - mediated exaggerated peristalsis is studied in Mayflower organ baths using isolated segments of guinea pig ileum (Holzer et al., J. Pharmacol. Exp. Ther. 1995; 274: 322-328). The lumen of ileal segments is perfused with Krebs-Henseleit solution, and intraluminal pressures are continuously recorded. During perfusion, each ileal segment fills gradually, and hence, the intraluminal pressures rise until they reach a threshold at which peristalsis is triggered, i.e. an aborally moving wave of peristaltic contractions. Any wave of peristaltic contractions results in a spike-like increase in intraluminal pressure and causes a partial emptying of fluid from the segment. Pressure thresholds triggering peristaltic contractions are used to quantify the effects of the compound of formula II. Cumulative application of substance P (1 nM up to 30  $\mu$ M evokes exaggerated peristaltic events by lowering the thresholds necessary to trigger peristaltic contractions. The effects of substance P are concentration-dependent with a  $pD_2$  value of 7.20. The compound of formula II (30 nM and 100 nM) competitively inhibits the substance P - evoked exaggerated peristalsis with apparent  $pA_2$  values of 7.35 and 7.23 respectively.

#### Example 3

Epithelial secretion is tested in submucosa/mucosa preparations of guinea pig colon. Using Ussing chamber techniques (Frieling et al., Naunyn Schmiedebergs Arch. Pharmacol. 1999; 359: 71-79) short circuit currents are recorded, and epithelial secretion (electrogenic chloride secretion) is stimulated via cumulative treatment with substance P (0.1 nM up to 10  $\mu$ M); it triggers secretion (increases in short circuit currents) in a concentration-dependent fashion ( $pD_2 = 7.50$ ). The compound of formula II (30 nM, 100 nM, and 300 nM) competitively inhibits substance P - induced electrogenic chloride secretion; a Schild plot analysis reveals a  $pA_2$  value of 7.94.

Claims

## 1. The use of a compound of formula I



in free form or in the form of a pharmaceutically acceptable salt for the preparation of a medicament for the treatment of a functional motility disorder of the viscera, wherein

$R^1$  is phenyl that is unsubstituted or is substituted by 1, 2 or 3 substituents selected from the group halogen,  $C_1$ - $C_7$ -alkyl, trifluoromethyl, hydroxy and  $C_1$ - $C_7$ -alkoxy,

$R^2$  is hydrogen or  $C_1$ - $C_7$ -alkyl,


$R^3$  is hydrogen,  $C_1$ - $C_7$ -alkyl or phenyl that is unsubstituted or is substituted by 1, 2 or 3 substituents selected from the group halogen,  $C_1$ - $C_7$ -alkyl, trifluoromethyl, hydroxy and  $C_1$ - $C_7$ -alkoxy,

$R^4$  is phenyl that is unsubstituted or is substituted by 1, 2 or 3 substituents selected from the group halogen,  $C_1$ - $C_7$ -alkyl, trifluoromethyl, hydroxy and  $C_1$ - $C_7$ -alkoxy; or is naphthyl, 1H-indol-3-yl or 1- $C_1$ - $C_7$ -alkyl-indol-3-yl,

$R^5$  and  $R^6$  are each independently of the other hydrogen or  $C_1$ - $C_7$ -alkyl, at least one of  $R^5$  and  $R^6$  being hydrogen, and

$R^7$  is  $C_3$ - $C_8$ -cycloalkyl, D-azacycloheptan-2-on-3-yl or L-azacycloheptan-2-on-3-yl.

## 2. Use according to claim 1, in which the compound of formula I is of formula IA



where \* denotes the R configuration and  $R^1$ ,  $R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^6$  and  $R^7$  are as defined in claim 1.

3. Use according to claim 1 or 2, in which

R<sup>1</sup> is phenyl, 3,5-bistrifluoromethyl-phenyl or 3,4,5-trimethoxyphenyl,

R<sup>2</sup> is hydrogen or C<sub>1</sub>-C<sub>7</sub>-alkyl,

R<sup>3</sup> is hydrogen or phenyl,

R<sup>4</sup> is phenyl, halo-phenyl, dihalo-phenyl, trihalo-phenyl, 2-naphthyl, 1H-indol-3-yl or 1-C<sub>1</sub>-C<sub>7</sub>-alkyl-indol-3-yl,

R<sup>5</sup> and R<sup>6</sup> are each independently of the other hydrogen or C<sub>1</sub>-C<sub>7</sub>-alkyl, at least one of R<sup>5</sup> and R<sup>6</sup> being hydrogen, and

R<sup>7</sup> is C<sub>5</sub>-C<sub>7</sub>cycloalkyl, D-azacycloheptan-2-on-3-yl or L-azacycloheptan-2-on-3-yl.

4. Use according to claim 1 or 2, in which

R<sup>1</sup> is 3,5-bistrifluoromethyl-phenyl,

R<sup>2</sup> is hydrogen, methyl or ethyl,

R<sup>3</sup> is hydrogen or phenyl,

R<sup>4</sup> is phenyl, 4-chlorophenyl, 4-fluorophenyl, 3,4-dichloro-phenyl, 3,4-difluoro-phenyl, 3-fluoro-4-chloro-phenyl, 3,4,5-trifluoro-phenyl, 2-naphthyl, 1H-indol-3-yl or 1-methyl-indol-3-yl,

R<sup>5</sup> and R<sup>6</sup> are each independently of the other hydrogen or methyl, at least one of R<sup>5</sup> and R<sup>6</sup> being hydrogen, and

R<sup>7</sup> is cyclohexyl, D-azacycloheptan-2-on-3-yl or L-azacycloheptan-2-on-3-yl.

5. Use according to claim 1 or 2, in which

R<sup>1</sup> is 3,5-bistrifluoromethyl-phenyl,

R<sup>2</sup> is hydrogen or methyl,

R<sup>3</sup> is hydrogen or phenyl,


R<sup>4</sup> is phenyl, 4-chlorophenyl, 3,4-dichloro-phenyl, 2-naphthyl, 1H-indol-3-yl or 1-methyl-indol-3-yl,

R<sup>5</sup> and R<sup>6</sup> are hydrogen, and

R<sup>7</sup> is cyclohexyl, D-azacycloheptan-2-on-3-yl or L-azacycloheptan-2-on-3-yl.

6. Use according to claim 1, in which the compound of formula I is a compound of formula

13



7. Use according to any one of claims 1 to 6, in which the disorder is associated with visceral hypersensitivity and/or altered motor responses.
8. Use according to claim 7, in which the disorder is a functional bowel disorder or functional gastrointestinal disorder.
9. Use according to claim 8, in which the disorder is irritable bowel syndrome or functional dyspepsia.